Orlistat

Overview

Orlistat, sold under the brand name Xenical among others, is a medication used to treat obesity. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.[1] WP

Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.[2][3] WP

The effectiveness of orlistat in promoting weight loss is definite but modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kg more than those not taking the drug over the course of a year. Orlistat also modestly reduces blood pressure and appears to prevent the onset of type 2 diabetes, whether from the weight loss itself or other effects. It reduces the incidence of diabetes type 2 in people who are obese around the same amount that lifestyle changes do.[4][5] WP⚠ The source also gives this in other units.

Benefits aside, however, orlistat is noted for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). They decrease with time, however, and are the most frequently reported adverse effects of the drug. In Australia, the United States and the European Union, orlistat is available for sale without a prescription. Over-the-counter approval was controversial in the United States, with consumer advocacy group Public Citizen repeatedly opposing it on safety and efficacy grounds. Generic formulations of orlistat are available in some countries. In Australia it has been listed as an S3 medication, available from a pharmacist without a prescription, since 2000.[1][6][7][8] WP

Uses, dosage and effects

Medical uses

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight—up to 35% of the weight they had lost. It reduces the incidence of diabetes type 2 in people who are obese around the same amount that lifestyle changes do. Long-term use of orlistat also leads to a very modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).[1][5][9] WP

Risks and side effects

Contraindications

Orlistat is contraindicated in:[1] WP

• Malabsorption[1] WP
• Hypersensitivity to orlistat[1] WP
• Reduced gallbladder function (e.g. after cholecystectomy)[1] WP
• Pregnancy and breastfeeding[1] WP
• Anorexia and Bulimia[1] WP
• Use caution with: obstructed bile duct, impaired liver function, and pancreatic disease[1] WP

Side effects

The primary side effects of the drug are gastrointestinal-related, and include steatorrhea (oily, loose stools with excessive flatus due to unabsorbed fats reaching the large intestine), fecal incontinence and frequent or urgent bowel movements. To minimize these effects, foods with high fat content should be avoided; the manufacturer advises consumers to follow a low-fat, reduced-calorie diet. Oily stools and flatulence can be controlled by reducing the dietary fat content to somewhere in the region of 15 grams per meal. The manual for Alli makes it clear that orlistat treatment involves aversion therapy, encouraging the user to associate eating fat with unpleasant treatment effects.[10][11][12] WP

Side effects are most severe when beginning therapy and may decrease in frequency with time; it has also been suggested that the decrease in side effects over time may be associated with long-term compliance with a low-fat diet.[1][13] WP

On 26 May 2010, the U.S. Food and Drug Administration (FDA) approved a revised label for Xenical to include new safety information about cases of severe liver injury that have been reported rarely with the use of this medication.[14] WP

An analysis of over 900 orlistat users in Ontario showed that their rate of acute kidney injury was more than triple that of non-users.[15] WP

A study from 2013 looked at 94,695 participants receiving orlistat in the UK between 1999 and 2011. The study showed no evidence of an increased risk of liver injury during treatment. They concluded:[16] WP

The incidence of acute liver injury was higher in the periods both immediately before and immediately after the start of orlistat treatment. This suggests that the observed increased risks of liver injury linked to the start of treatment may reflect changes in health status associated with the decision to begin treatment rather than any causal effect of the drug. WP

Long-term

Despite a higher incidence of breast cancer amongst those taking orlistat in early, pooled clinical trial data—the analysis of which delayed FDA review of orlistat—a two-year study published in 1999 found similar rates between orlistat and placebo (0.54% versus 0.51%), and evidence that tumors predated treatment in 3 of the 4 participants who had them. There is evidence from an in vitro study to suggest that the introduction of specific varied preparations containing orlistat, namely the concurrent administration of orlistat and the monoclonal antibody trastuzumab, can induce cell death in breast cancer cells and block their growth.[17][18][19] WP⚠ A word may be missing here. It reads this way in the source too.

Fecal fat excretion promotes colon carcinogenesis. In 2006 the results of 30-day study were published indicating that orlistat at a dosage of 200 mg/kg chow administered to rats consuming a high-fat chow and receiving two 25 mg/kg doses of the potent carcinogen 1,2-dimethylhydrazine produced significantly higher numbers of aberrant crypt foci (ACF) colon lesions than did the carcinogen plus high-fat chow without orlistat. ACF lesions are believed to be one of the earliest precursors of colon cancer.[20][21] WP

Precautions

Absorption of fat-soluble vitamins and other fat-soluble nutrients is inhibited by the use of orlistat.[1] WP

Interactions

Interactions

Orlistat may reduce plasma levels of ciclosporin (also known as "cyclosporin" or "cyclosporine", trade names Sandimmune, Gengraf, Neoral, etc.), an immunosuppressive drug frequently used to prevent transplant rejection; the two drugs should therefore not be administered concomitantly. Orlistat can also impair absorption of the antiarrhythmic amiodarone. The Medicines and Healthcare products Regulatory Agency (MHRA) has suggested the possibility that orlistat could reduce the absorption of antiretroviral HIV medications.[1][22][23] WP

The opioid receptor agonist loperamide assists with stool consistency in individuals taking orlistat. Continence problems caused by how orlistat blocks the absorption of fat were found to be improved with loperamide intervention.[24] WP

Pharmacology

Mechanism of action

Orlistat works by inhibiting gastric and pancreatic lipases, the enzymes that break down triglycerides in the intestine. When lipase activity is blocked, triglycerides from the diet are not hydrolyzed into absorbable free fatty acids, and instead are excreted unchanged. Only trace amounts of orlistat are absorbed systemically; the primary effect is local lipase inhibition within the GI tract after an oral dose. The primary route of elimination is through the feces.[25][26] WP

Orlistat was also found to inhibit the thioesterase domain of fatty acid synthase (FAS), an enzyme involved in the proliferation of cancer cells but not normal cells. However, potential side effects of orlistat, such as inhibition of other cellular off-targets or poor bioavailability, might hamper its application as an effective antitumor agent. One profiling study undertook a chemical proteomics approach to look for new cellular targets of orlistat, including its off-targets. Orlistat also shows potential activity against the Trypanosoma brucei parasite.[27][28] WP

Orlistat prevents approximately 30% of dietary fat from being absorbed.[29] WP

Legal status

Legal status

Orlistat is available both with and without a prescription.[1][30][31][32] WP

Australia and new zealand

In Australia and New Zealand, orlistat is available as a "Pharmacist Only Medicine". In 2007, the Committee decided to keep orlistat as a Schedule 3 drug, but withdrew its authorization of direct-to-consumer Xenical advertising, stating this "increased pressure on pharmacists to provide orlistat to consumers...this in turn had the potential to result in inappropriate patterns of use".[8][33] WP

United states

Orlistat was initially approved by the U.S. Food and Drug Administration in April 1999 as a prescription-only medication. On 23 January 2006, an FDA advisory panel voted 11 to 3 to recommend the approval of an OTC formulation of orlistat, to be sold under the brand name Alli by GlaxoSmithKline. Approval was granted on 7 February 2007, and Alli became the first weight loss drug officially sanctioned by the U.S. government for over-the-counter use. Consumer advocacy organization Public Citizen opposed over-the-counter approval for orlistat.[7][34–37] WP

Alli became available in the U.S. in June 2007. It is sold as 60 mg capsules—half the dosage of prescription orlistat.[7][37] WP

European union and switzerland

On 21 January 2009, the European Medicines Agency granted approval for the sale of orlistat without a prescription.[30][38] WP

At least since September 2017, tablets with 60 mg orlistat can be freely sold in Swiss drugstores. Formulations with 120 mg per tablet require a prescription, but can be sold without one in pharmacies under an exemption rule, which is based on a list of easily diagnosable diseases.[39] WP

Generic formulations

U.S. patent protection for Xenical, originally to end on 18 June 2004, was extended by five years (until 2009) by the U.S. Patent and Trademark Office. The extension was granted on 20 July 2002, and expired on 18 June 2009.[40][41] WP

Generic orlistat is available in Iran under the brand Venustat manufactured by Aburaihan Pharmaceutical co., in India, under the brands Orlean (Eris), Vyfat, Olistat, Obelit, Orlica and Reeshape. In Russia, orlistat is available under the brand names Xenical (Hoffmann–La Roche), Orsoten/Orsoten Slim (KRKA d. d.) and Xenalten (OBL-Pharm). In Austria, orlistat is available under the brand name Slimox. In Malaysia, orlistat is available under the brand name Cuvarlix and is marketed by Pharmaniaga. In the Philippines orlistat is available under the brand name RedoXfat Plus manufactured by ATC Healthcare[42] WP

Cost

At times, such as in spring 2012, orlistat has come into short supply, with consequent price increases because of nonavailability of one of the drug's components.[43] WP

Counterfeit products

In January 2010, the U.S. Food and Drug Administration issued an alert stating that some counterfeit versions of Alli sold over the Internet contain no orlistat, and instead contain the weight-loss drug sibutramine. The concentration of sibutramine in these counterfeit products is at least twice the amount recommended for weight loss.[44] WP

Chemistry

Formula

C29H53NO5 PC

CAS number

96829-58-2 PC

Molar mass (g/mol)

495.7 PC

IUPAC name (computed by PubChem)

[(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate PC

SMILES

CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O PC

InChIKey

AHLBNYSZXLDEJQ-FWEHEUNISA-N PC

PubChem CID

3034010

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Xenical- orlistat capsule. 9 December 2021
2. Journal / agency Barbier P, Schneider F. Syntheses of tetrahydrolipstatin and absolute configuration of tetrahydrolipstatin and lipstatin. Helvetica Chimica Acta. 1987. doi:10.1002/hlca.19870700124
3. Journal / agency Pommier A, Pons M, Kocienski P. The first total synthesis of (−)-lipstatin. Journal of Organic Chemistry. 1995. doi:10.1021/jo00127a045
4. Journal / agency Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. The Cochrane Database of Systematic Reviews. 2004. doi:10.1002/14651858.CD004094.pub2 · PMID 15266516 · PMC8078201
5. Journal / agency Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. February 2007. doi:10.1136/bmj.39063.689375.55 · PMID 17237299 · PMC1796695
6. Other POISONS STANDARD JUNE 2017. June 2017
7. Other Schmid RE. FDA OKs First Nonprescription Diet Pill. 9 February 2007
8. Other Orlistat 120mg capsule blister pack. 11 April 2000
9. Journal / agency Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, Semlitsch T. Long-term effects of weight-reducing drugs in people with hypertension. The Cochrane Database of Systematic Reviews. January 2021. doi:10.1002/14651858.CD007654.pub5 · PMID 33454957 · PMC8094237
10. Other Treating Obesity
11. Other FDA Approves alli (orlistat 60 mg capsules) Over-The-Counter. 7 February 2007
12. Other Alli Companion Guide. 2007
13. Journal / agency Mancini MC, Halpern A. Pharmacological treatment of obesity. Arquivos Brasileiros de Endocrinologia e Metabologia. April 2006. doi:10.1590/S0004-27302006000200024 · PMID 16767304
14. Journal / agency FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. 28 June 2019
15. Journal / agency Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, Wald R, Garg AX. Orlistat and acute kidney injury: an analysis of 953 patients. Archives of Internal Medicine. April 2011. doi:10.1001/archinternmed.2011.103 · PMID 21482850
16. Journal / agency Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. April 2013. doi:10.1136/bmj.f1936 · PMID 23585064 · PMC3624963
17. Other Kolata G. Obesity Drug Can Lead to Modest Weight Loss, Study Finds. 20 January 1999
18. Journal / agency Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. January 1999. doi:10.1001/jama.281.3.235 · PMID 9918478
19. Journal / agency Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Annals of Oncology. August 2005. doi:10.1093/annonc/mdi239 · PMID 15870086
20. Journal / agency Garcia SB, Barros LT, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, Vespúcio MV, Uyemura SA. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Letters. August 2006. doi:10.1016/j.canlet.2005.09.011 · PMID 16377080
21. Journal / agency Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. The New England Journal of Medicine. October 1998. doi:10.1056/NEJM199810293391803 · PMID 9791143
22. Journal / agency Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. Journal of Clinical Pharmacology. April 2003. doi:10.1177/0091270003252236 · PMID 12723464
23. Other Orlistat: theoretical interaction with antiretroviral HIV medicines. 13 March 2014
24. Journal / agency Fox M, Stutz B, Menne D, Fried M, Schwizer W, Thumshirn M. The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. Digestive Diseases and Sciences. September 2005. doi:10.1007/s10620-005-2900-6 · PMID 16133954
25. Journal / agency Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. March 2000. doi:10.1592/phco.20.4.270.34882 · PMID 10730683 · PMC6145169
26. Other Higham G. Orlistat & Xenical: Do Weight Loss Pills Work? | e-Surgery. 5 June 2020
27. Journal / agency Yang PY, Liu K, Ngai MH, Lear MJ, Wenk MR, Yao SQ. Activity-based proteome profiling of potential cellular targets of Orlistat--an FDA-approved drug with anti-tumor activities. Journal of the American Chemical Society. January 2010. doi:10.1021/ja907716f · PMID 20028024
28. Journal / agency Yang PY, Wang M, Liu K, Ngai MH, Sheriff O, Lear MJ, Sze SK, He CY, Yao SQ. Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent. Chemistry: A European Journal. July 2012. doi:10.1002/chem.201200482 · PMID 22674877
29. Other 2006 Physicians' Desk Reference (PDR). 2006
30. Other Chemists to provide obesity pill. 21 January 2009
31. Journal / agency Alli- orlistat capsule. 9 November 2020
32. Journal / agency Orlistat. 16 February 2012
33. Other Scheduling of orlistat. 22 February 2007
34. Other Stolberg S. F.D.A. Approves Fat-Blocking Anti-Obesity Drug. 27 April 1999
35. Other Panel Supports Offering Diet Pill Orlistat Over the Counter. 24 January 2006
36. Journal / agency FDA Approves Orlistat for Over-the-Counter Use. 7 February 2007
37. Other Saul S. Weight-Loss Drug to Be Sold Over the Counter. 7 February 2007
38. Other GlaxoSmithKline receives European Commission approval to market alli (orlistat 60mg). 21 January 2009
39. Other directory of drugs approved in Switzerland. link 2
40. Other Rogan JE. Certificate Extending Patent Term Under 35 U.S.C. § 156. 30 July 2002
41. Other Drug Patent Expirations in June 2009. 1 June 2009
42. Other Devarajan U. Fatty issues. 1 March 2009
43. Other Jeanne Whalen. Glaxo Sells Bulk of Over-the-Counter Drugs. 20 April 2012
44. Other Fake Alli diet pills can pose health risks. 23 January 2010

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.